A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pembrolizumab; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics; Registrational
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 24 Jan 2023 Planned primary completion date changed from 10 Feb 2023 to 4 Apr 2023.
- 06 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Jul 2022 Planned number of patients changed from 450 to 512.